SPRAVATO is emerging as a groundbreaking way to reduce symptoms of depression and suicidal thoughts quickly and effectively. Advances in science now allow providers to safely harness the healing power of ketamine through a controlled, FDA-cleared nasal spray.
For those struggling with their mental health and still searching for relief, SPRAVATO may be able to support you on your journey toward wellness. Our team at The Nexus Group PC is here to help you understand your options for treatment. After reviewing these SPRAVATO FAQs, we encourage you to contact us to learn whether this innovative treatment may be right for you.
Many people have questions about SPRAVATO’s safety and regulatory status. SPRAVATO is fully cleared by the U.S. Food and Drug Administration (FDA) for adults with treatment-resistant depression (TRD) and suicidal ideation (SI). Initially authorized in 2019 as an adjunct therapy to traditional antidepressants, it received approval in 2025 for use as a standalone treatment. This expanded approval allows more individuals to access its benefits.
SPRAVATO has been clinically proven to reduce depression symptoms quickly and effectively, especially for those who have not responded to conventional therapies. Studies indicate that about 88% of patients who use SPRAVATO experience noticeable improvement within three months, with some achieving complete symptom relief.
Your SPRAVATO nasal spray dose will be delivered in our office under the careful supervision of one of our clinicians, who will monitor your mental and physical health for about two hours to ensure your safety. Your treatment will be administered on a structured, phase-based dosing schedule that begins with sessions twice per week for about one month, then once per week for an additional month, then as needed for ongoing maintenance.
One of the most attractive features of SPRAVATO is how quickly it can work. Many patients report symptom relief within just 24 hours of their first dose, and results continue to improve over time. This fast-acting quality makes SPRAVATO especially valuable for individuals dealing with severe depression, suicidal thoughts, or acute emotional distress. With that said, if you are experiencing a mental health emergency, it is important to seek immediate professional care.
SPRAVATO contains esketamine, which can cause sedation. During and right after your treatment, you may feel temporarily drowsy, dizzy, or dissociated. For safety reasons, patients are required to arrange transportation home after each treatment. Your safety during and after sessions is our top priority.
Adults in good overall health who are dealing with treatment-resistant depression or suicidal thoughts may qualify for SPRAVATO. Patients with certain uncontrolled medical conditions, such as high blood pressure or a history of brain bleeds or substance abuse, may not be good candidates for this treatment. It is also not recommended for those who are pregnant or breastfeeding.
The best way to know if Spravato is appropriate for you is by scheduling an initial consultation at our office. Here, one of our board-certified psychiatry providers will ask you questions about your medical and psychiatric history, past treatments you have tried, and mental health goals. We will also conduct a mental health intake assessment, which we can use to determine whether SPRAVATO will be a good option for you and begin to develop an individualized treatment plan.
For individuals living with treatment-resistant depression, SPRAVATO can offer meaningful, life-changing relief. If you still have questions after reviewing these SPRAVATO FAQs, reach out to our team to schedule an initial appointment and learn more about how this advanced treatment could support your mental health goals.
